Hepatitis D in people with chronic hepatitis B in Vietnam
Official title: Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection
Run by Tam Anh Research Institute · NCT06638320 · Data updated 2026-11-12
This observational study tests how common hepatitis D is among people with chronic hepatitis B and looks at the types of HDV and related factors.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 2452 (estimated) |
| Sponsor | Tam Anh Research Institute Academic / other |
| Locations | 3 sites (Hà Nội, Northern Vietnam and 2 other locations) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | November 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT06638320 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults and adolescents aged 16 and older with chronic hepatitis B (HBsAg positive for at least six months, or HBsAg positive with total anti-HBc positive and IgM anti-HBc negative) who are patients or inpatients at the participating centers.
✕Probably not a fit
Participants who do not have chronic hepatitis B or who do not consent may not benefit from findings or testing beyond standard care.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This cross-sectional study enrolls patients with chronic hepatitis B from several hospitals in Vietnam to measure HDV prevalence and genotype distribution. Researchers collect questionnaire data on epidemiologic risk factors and obtain a blood sample for testing. The study aims to identify factors related to HDV infection, including vaccination history, drug use, family and environmental factors, and lifestyle. Only individuals who consent and meet the HBV criteria are eligible to participate, and data collection occurs at multiple hospital sites. No experimental interventions are planned; the study is purely observational.
Why it matters
Potential benefit: If successful, the study could improve understanding of HDV burden among HBV patients and guide screening and public health strategies.
How similar studies have gone: Previous research has shown HDV can be prevalent among HBV patients in some regions, supporting the value of region-specific prevalence data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 16 years old undergo testing at the Testing Center of Tam Anh General Hospital or Tam Anh TP. Ho Chi Minh General Hospital, with chronic hepatitis B HBsAg (+) standards for six months or over or HBsAg (+) combined with HBcAb total (+) and HBcAb-immunoglobulin M (-). * Patients ≥ 16 years old with chronic hepatitis B come to be examined or are inpatients at the Gastroenterology - Hepatobiliary Center of Bach Mai Hospital, diagnosed with hepatocellular carcinoma, and cirrhosis Exclusion Criteria: * Patients do not agree to participate in the study or refuse to sign a written informed consent.
Where it's running
-
Bach Mai General Hospital
Hà Nội, Northern Vietnam, Vietnam Recruiting -
Tam Anh General Hospital
Hà Nội, Northern Vietnam, Vietnam Recruiting -
Tam Anh TP. Ho Chi Minh General Hospital
Ho Chi Minh City, Southern Vietnam, Vietnam Recruiting
Study contacts
- Study coordinator: Loc Tho Truong, MSc
- Email: loctt@tamri.vn
- Phone: +842871026789
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of functional cure on patient-reported outcomes in chronic hepatitis B
This study tests whether people with chronic hepatitis B who achieve a functional cure have better patient-reported outcomes compared to those not cured, relapse, or healthy controls.
-
Sequential combination therapy for functional cure of chronic hepatitis B
This trial tests a new two-drug approach to see if adding immunotherapy to ongoing HBV treatment can lead to loss of hepatitis B surface antigen in adults with chronic hepatitis B.
-
Combination therapy for functional cure in chronic hepatitis B
This phase 2 trial tests whether a sequence of anti-PD-1/PD-L1 antibodies with pegylated interferon and nucleos(t)ide analogues can achieve functional cure (HBsAg loss) in adults with chronic hepatitis B.
-
GST-HG131/GST-HG141 tablets vs placebo in chronic hepatitis B
A phase IIa trial tests GST-HG131 and GST-HG141 tablets against placebo to see if they are safe and help people with chronic hepatitis B.
-
AHB-137 injection in people with chronic hepatitis B
This study tests AHB-137 vs placebo in adults with chronic hepatitis B who have not yet received antiviral treatment.
-
AHB-137 injection pharmacokinetics and safety in people with mild to moderate liver dysfunction and normal liver function
This study tests how AHB-137 behaves in the body and its safety in adults with chronic hepatitis B who have mild to moderate liver problems or normal liver function.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.